Jiang and He et al. show that during vascular migration, circulating tumor cells release antigen-enriched migrasomes, which stimulate anti-metastatic immunity. bit.ly/4em1W1J

Menzel, Zhou et al. observed persisting responses to ICB in melanoma patients and orthotopic tumor mouse models upon complete regional tumor-draining lymph node (LN) dissection. bit.ly/4zimpfU  @harvardmed.bsky.social

Using a computational strategy, Radman et al. mutated the constant and transmembrane regions of the MART-1 DMF4 TCR α/β chains to reduce mispairing and improve expression. bit.ly/3Vu61KU  @goodmanfaculty.bsky.social

Noblecourt and Wicki et al. showed that carboplatin and paclitaxel (CarboTaxol) with viral vector vaccines expanded antigen-specific TCF1+CD8+ T cells during priming, slowed tumor growth, and improved survival in mouse models. bit.ly/4hzGokl   @ludwigcancer.bsky.social

Messemaker and Kwee et al. developed a TCR rapid assembly platform (T-RAP) that could be used to evaluate TCR reactivity acir.org/weekly-dige... @schumacher-lab.bsky.social @nkinl.bsky.social

Malinconico et al. engineered T cells with both a CAR targeting CD176 (expressed in NSCLC and other tumors), and an inducible cassette encoding either IL-18 or IL-12 that would be expressed following CAR activation of NF-κB.   @aacrjournals.bsky.social bit.ly/4rFOStG

Lin et al. engineered an oncolytic herpesvirus (oHSV) with a PD-L1 nanobody attached to gD on the viral envelope surface (gDαPD- L1), targeting the virus to both tumors and TAMs expressing PD-L1. bit.ly/3VlMNHh

St. Paul and Hendrikse et al. used single-cell sequencing and developed a machine-learning algorithm (PreGame) to distinguish the enigmatic tumor-reactive γδ T cells (TRγδ T cells) from bystander cells and confirm their specificity.  @pmresearch-uhn.bsky.social bit.ly/4ypCkcg

Duzagac et al. characterized circulating neoantigen-specific T cells in Lynch syndrome (LS) carriers using functional assays, single-cell RNA/TCR sequencing, and integration with existing TCR datasets.  @mdanderson.bsky.social bit.ly/4yXP9dG

Hwang et al. engineered high-affinity antibodies against HLA-E–VL9 using structure-based design and high-throughput library screening to block inhibitory NKG2A/CD94 interactions.  @dukemedschool.bsky.social bit.ly/4iRh2iZ

Using novel Tg mouse models, Xu et al. identified a TCR specific for a clinically relevant epitope rarely expressed on CD8+ T cells in chronic HBV infection. bit.ly/4hTDYNr

New combination for PDAC acir.org/weekly-dige... @danafarber.bsky.social @harvardcellbio.bsky.social

Asano, Veatch, and Sung et al. identified TCRMCC1, a high-avidity HLA-A*02:01-restricted TCR targeting Merkel cell polyomavirus large-T antigen and treated seven patients who had ICI-refractory metastatic MCC using autologous TCRMCC1-transduced [...] @fredhutch.org bit.ly/46BEhGz

Using scRNA sequencing, Ng et al. compared LN biopsy samples (non-affected vs. tumor-affected) from SCLC patients to study the antitumor role of MHC-I-independent pathways. bit.ly/4rAAbrS   @wehi-research.bsky.social

Smith, Dao, and Gavil et al. showed that activation of unexhausted non-tumor-specific memory T cells in the TIME induced tumor clearance in the absence of NK cell- or TCRαβ-dependent tumor cell recognition, although the latter[...] bit.ly/4AsZ38H @oliviacs.bsky.social @cfi-umn.bsky.social

Qing and Ghorani et al. explored mechanisms of secondary resistance (2°R) to therapy (Treg depletion via anti-CD25 mAb + GM-CSF-expressing tumor cell vaccine) in B16 tumor- bearing mice.  @aacrjournals.bsky.social bit.ly/4h9JjA1

Haratani et al. found that most neoantigens arising from truncal mutations in TP53 were not presented, either because they arose from processing-resistant regions of p53 or because the required HLA allele was absent. bit.ly/4ArRQ91  @danafarbernews.bsky.social

Falcomatà et al. used perturb-map spatial functional genomics to identify tumor-derived extracellular factors that promote PDAC immune evasion. bit.ly/4yaTJ8r @chiarafalcomata.bsky.social @brownlab1.bsky.social

PLA2G2D, produced by a unique subset of lymph node macrophages, suppresses T cells and could be targeted for immunotherapy acir.org/weekly-dige...

Ibrahim et al. profiled sotorasib-induced changes in syngeneic KRASG12C/Trp53−/− lung and colon carcinoma models with and without anti-PD-1. bit.ly/4h4qUTW  @aacrjournals.bsky.social

Tian et al. fused second-generation CAR-macrophages with neutrophils, generating syncytial (S)-CAR-M with enhanced chemokine-driven solid tumor infiltration and cytotoxicity. bit.ly/4xZBIda

Golubovskaya et al. showed that intratumoral delivery of an anti-human EpCAM-CD3 BiTE mRNA-LNP stops growth of only directly injected EpCAM+ human tumor xenografts in immuno-incompetent mice (with i.v. human T cells). bit.ly/3Typnha

Xiang et al. developed a DC-directed dual pH-gated hybrid nanoparticle (HNP) that sequentially releases αCD47 peptides in the acidic TIME to enhance antigen acquisition and subsequently cGAMP under endosomal acidification to activate intracellular STING. bit.ly/3SMR1a3

Nishida et al. sought to prevent carcinogen (NMU)-induced mammary tumorigenesis in outbred Sprague-Dawley rats by targeting LALBA, a protein specifically expressed in luminal progenitor (LP) cells – the proposed cell-of-origin for breast cancer. bit.ly/3UZwj7q

Fine-tuning IL-2 delivery for cancer immunotherapy acir.org/weekly-dige...

Lin et al. developed a longitudinal scRNAseq atlas of 441 ICI-treated tumors from 241 patients across 10 cancer types, and identified 4 conserved TIME states. bit.ly/3SYlx0t

Groeneveldt et al. investigated mechanisms driving early-stage immune-related adverse events (irAEs) in patients with metastatic melanoma treated with combination ICB (anti-PD-1 and anti-CTLA-4). bit.ly/4A4rx8O  @aacrjournals.bsky.social

Swatler, Puccio, et al. used scRNsSeq and flow cytometry to define Treg subsets and analyze heterogeneity and TCR overlap across tissues from 9 tumor types. bit.ly/4yo9RTL

Liu et al. developed a genome-wide in vivo CRISPR screening platform using a T cell-attracting anti-CD3 scFv-expressing A375 tumor model and primary human T cells to identify in vivo regulators of intratumoral T cell abundance and effector function. bit.ly/4xhHzth

Arisato et al. found that the LLC-2B2 subclone of LLC was universally rejected in ICB-treated WT mice and was also rejected in 36% of ICB-treated Batf3-/- mice. In Batf3-/- mice, rejection was dependent on CD8+ T cells primed by alternative XCR1- APCs, which [...] bit.ly/3SF8l0B